Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix (NCT04723095) | Clinical Trial Compass
RecruitingNot Applicable
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
United States750 participantsStarted 2013-05-16
Plain-language summary
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:
* Small cell neuroendocrine carcinoma
* Large cell neuroendocrine carcinoma
* Undifferentiated high-grade neuroendocrine carcinoma
* Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
* Patients with all stages of disease are considered eligible
* Patients who do not speak English can be eligible if accompanied by an institutional interpreter
* Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
* Patient may be residents of any country and be of any ethnic background
* Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
* Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
* Next of kin or legal authorized representatives of patients must read and speak English
Exclusion Criteria:
* Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Disease characterization data
Timeframe: through study completion, an average of 1 year
2
Patient treatment data
Timeframe: through study completion, an average of 1 year
3
Patient outcome data
Timeframe: through study completion, an average of 1 year